Trial Profile
A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2019
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Hakko Kirin Korea; Kyowa Kirin
- 20 May 2015 Results presented at the 111th International Conference of the American Thoracic Society.
- 28 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.